| Title | Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis |
| Authors | Zheng, Wei Xiang, Ying-Qiang Li, Xian-Bin Ungvari, Gabor S. Chiu, Helen F. K. Sun, Feng D'Arcy, Carl Meng, Xiangfei Xiang, Yu-Tao |
| Affiliation | Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Guangdong, Peoples R China. China Clin Res Ctr Mental Disorders, Beijing, Peoples R China. Beijing Inst Brain Disorders, Ctr Depress, Beijing, Peoples R China. Capital Med Univ, Beijing Anding Hosp, Beijing Key Lab Mental Disorders, Beijing, Peoples R China. Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA, Australia. Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China. Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing, Peoples R China. Univ Saskatchewan, Dept Psychiat, Saskatoon, SK, Canada. Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, Canada. McGill Univ, Dept Psychiat, Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada. Univ Macau, Fac Hlth Sci, Unit Psychiat, Taipa, Peoples R China. Univ Macau, Fac Hlth Sci, 3-F,Bldg E12,Ave Univ, Taipa, Peoples R China. Zheng, W (reprint author), Guangzhou Huiai Hosp, Guangzhou, Guangdong, Peoples R China. |
| Keywords | antipsychotic cognitive function huperzine A schizophrenic-spectrum disorders systematic review meta-analysis ACETYLCHOLINESTERASE INHIBITORS ACHEIS CHOLINESTERASE-INHIBITORS VISUAL HALLUCINATIONS ALZHEIMERS-DISEASE CLINICAL-TRIALS THERAPY DISORDERS PROGRESS |
| Issue Date | 2016 |
| Publisher | HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL |
| Citation | HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL.2016,31(4),286-295. |
| Abstract | ObjectiveThe aim of this study was to examine the efficacy of huperzine A (HupA), an isolate of Huperzine serrata, in the treatment of cognitive deficits in schizophrenia spectrum disorders. MethodsPubMed, PsycINFO, Embase, Cochrane Library, Cochrane Controlled Trials Register, WanFang, Chinese Biomedical, and China Journal Net databases were searched from inception to 15 July 2015 for randomized controlled trials (RCTs) in English or Chinese of HupA augmentation of antipsychotic drug therapy versus placebo or ongoing antipsychotic treatment. ResultsTwelve RCTs (n=1117) lasting 11.76.0weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p<0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p=0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p=0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n=7)/Brief Psychiatric Rating Scale (n=1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p=0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p=0.20) and adverse events were similar between groups. ConclusionsThis review suggests that adjunctive HupA is an effective choice for improving cognitive function for patients with schizophrenia spectrum disorders. More well-designed RCTs are needed to further confirm HupA's efficacy. Copyright (c) 2016 John Wiley & Sons, Ltd. |
| URI | http://hdl.handle.net/20.500.11897/433345 |
| ISSN | 0885-6222 |
| DOI | 10.1002/hup.2537 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 公共卫生学院 |
